Search results
Results from the WOW.Com Content Network
Researchers found that removing the IL-11 gene or using an anti-IL-11 antibody dramatically increased the lifespan and health of aging mice. ... or extend life without improving health, IL-11 does ...
An anti-aging therapy led to an extension of life by 25% in a new animal study. Here, experts explain how it could affect longevity and lifespan. ... mice were treated with the anti-IL-11 drug, a ...
[8] [9] It was developed as a recombinant protein (rhIL-11) as the drug substance oprelvekin. The human IL-11 gene, consisting of 5 exons and 4 introns, is located on chromosome 19, [6] and encodes a 23 kDa protein. IL-11 is a member of the IL-6-type cytokine family, distinguished based on their use of the common co-receptor gp130.
They also showed a normal life span. In a study in which a single 50 μg/kg subcutaneous dose was administered to eighteen healthy men, the peak serum concentration (C max) of 17.4 ± 5.4 ng/mL was reached at 3.2 ± 2.4 h (T max) following dosing. The terminal half-life was 6.9 ± 1.7 hours.
Though the concept per se has been present in the life extension community since at least the 1970s (for example, Robert Wilson, essay Next Stop, Immortality, 1978 [67]). 2004 As a result of the use of anti-aging therapy, a team of scientists led by Stephen Spindler managed to extend the life of a group of already adult mice to an average of 3. ...
The "healthspan-lifespan gap" was largest in the U.S., as Americans live in poor health for an average of 12.4 years, compared to 10.9 years in 2000.
The normal life expectancy for 60 to 70 years old is 23 to 15 years; for 90 years old it is 4.5 years. [219] Following AD diagnosis it ranges from 7 to 10 years for those in their 60s and early 70s (a loss of 13 to 8 years), to only about 3 years or less (a loss of 1.5 years) for those in their 90s.
David Andrew Sinclair AO (born June 26, 1969) is an Australian-American biologist and academic known for his research on aging and epigenetics.Sinclair is a professor of genetics at Harvard Medical School and the founding director of the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging at Harvard.